EA
CPRX

Evolution Advisers’s Catalyst Pharmaceutical CPRX Stock Holding History

Evolution Advisers’s Portfolio CPRX Stock Details CPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$0 Buy
+7
New +$207 ﹤0.01% 364

Other funds holding CPRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $10.2B AUM 67.73% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Evolution Advisers's CPRX Position: Q2 2026 in Review

Evolution Advisers opened a new position in Catalyst Pharmaceutical (CPRX) in Q2 2026: 7 shares worth $0. The stake represents ﹤0.01% of the portfolio and ranks #364 among its holdings.

393 funds tracked by Wall St. Rank hold CPRX as of Q2 2026.

  • Evolution Advisers held 7 shares of Catalyst Pharmaceutical worth $0 as of Q2 2026.
  • Catalyst Pharmaceutical was a new Evolution Advisers position in Q2 2026.
  • Catalyst Pharmaceutical made up ﹤0.01% of Evolution Advisers's portfolio in Q2 2026, its #364 holding.
  • 393 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q2 2026.

Based on Evolution Advisers's 13F filing for Q2 2026, filed 31 Jul 2026.